Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | terminated | Phase 1 / Phase 2 | 15 | Evaxion Biotech A/SINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 45 | Apexigen America, Inc.INDUSTRY | 2 | Feb 13, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease | terminated | — | 2 | Vanderbilt University Medical CenterOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04663126 | Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma(Tilmanocept) | terminated | Early Phase 1 | 5 | John O. PriorOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib(Mel61) | terminated | Early Phase 1 | 8 | Craig L Slingluff, JrOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01856023 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma(PROCLIVITY02) | terminated | Phase 4 | 29 | Clinigen, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | terminated | Phase 2 | 6 | RAPT Therapeutics, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma(Mel63; CHAMP) | terminated | Phase 1 / Phase 2 | 48 | Craig L Slingluff, JrOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03272464 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | terminated | Phase 1 | 1 | Massachusetts General HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03430947 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases(RadioCoBRIM) | terminated | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02740920 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | terminated | Phase 2 | 9 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05266430 | Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)(IL) | terminated | — | 2 | Aura BiosciencesINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | terminated | — | 50 | Aristotle University Of ThessalonikiOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02203604 | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | terminated | Phase 2 | 9 | CINJRegulatoryOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04577729 | The IRMI-FMT Trial | terminated | N/A | 5 | Medical University of GrazOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT00104884 | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | terminated | Phase 2 | 4 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jun 28, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03060356 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | terminated | Early Phase 1 | 77 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | terminated | Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05848219 | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib | terminated | — | 543 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence(PIVOT-12) | terminated | Phase 3 | 765 | Nektar TherapeuticsINDUSTRY | 17 | Apr 21, 2023 | clinicaltrials |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment(METILDA) | terminated | Phase 2 | 2 | The Christie NHS Foundation TrustOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05234437 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | terminated | Phase 2 | 1 | QBiotics Group LimitedINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | terminated | Phase 2 | 47 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03878719 | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | terminated | Phase 1 | 1 | PfizerINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02591654 | MRI and PET to Assess Pembrolizumab Response(MPAK) | terminated | Early Phase 1 | 6 | Columbia UniversityOTHER | 1 | Dec 30, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 4, 2024source: clinicaltrials